Tech Company Financing Transactions

Ceptaris Therapeutics Funding Round

Ceptaris Therapeutics closed a $4 million Series B investment round on 11/13/2006. Investors included Osage Partners, BioAdvance Ventures and TDH Capital Corporation.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

101 Lindenwood Dr. 400
Malvern, PA 19355
USA

Phone

610-975-9290

Website

www.ceptaris.com

Email Address

[email protected]

Overview

Ceptaris Therapeutics Inc., a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Steve Tullman

        

Chief Medical Officer

Jeffrey Wilkins

        

Chief Operating Officer

Douglas Gssl

        

VP - Bus. Development

Evan Dick

        

VP - General Counsel

Kamil Ali-Jackson

        

VP - Operations

Jeffrey Shaver

        

VP - R & D

Timothy Henkel

        

Browse more venture capital transactions:

Prev: 11/13/2006: Cerenis Therapeutics venture capital transaction
Next: 11/13/2006: Mascoma venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary